Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act, 48092-48093 [2017-22284]
Download as PDF
48092
Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices
ethrower on DSK3G9T082PROD with NOTICES
As described in section III.D of the
guidance, those outsourcing facilities
that request a small business reduction
in the amount of the annual
establishment fee will receive a small
business designation letter notifying the
facility of FDA’s decision. Outsourcing
facilities eligible to pay a reduced fee
should maintain a copy of the small
business designation letter applicable to
that fiscal year for their records.
We estimate that annually a total of 15
outsourcing facilities (‘‘no. of
recordkeepers’’ in table 3) will keep a
copy of their small business designation
letter (‘‘total annual records’’ in table 3),
and that maintaining each record will
take 0.5 hour (‘‘average burden per
recordkeeping’’ in table 3).
As described in section V.B of the
guidance, an outsourcing facility may
request reconsideration under 21 CFR
10.75 of an FDA decision related to the
fee provisions of section 744K of the
FD&C Act. As explained in the
guidance, the request should state the
facility’s rationale for its position that
the decision was in error and include
any additional information that is
relevant to the outsourcing facility’s
argument.
We estimate that a total of three
outsourcing facilities (‘‘no. of
respondents’’ in table 2, row 2) annually
will submit to FDA a request for
reconsideration as described in the
guidance. We estimate that it will take
an outsourcing facility approximately 1
hour to prepare and submit to FDA each
request for reconsideration (‘‘average
burden per response’’ in table 2, row 2).
As described in section V.B of the
guidance, an outsourcing facility may
appeal, as set forth in § 10.75, an FDA
denial of a request for reconsideration of
an FDA decision related to the fee
provisions of section 744K of the FD&C
Act.
We estimate that a total of one
outsourcing facility (‘‘no. of
respondents’’ in table 2, row 3) annually
will submit an appeal of an FDA denial
of a request for reconsideration. We
estimate that it will take an outsourcing
facility 1 hour to prepare and submit
each appeal under § 10.75 (‘‘average
burden per response’’ in table 2, row 3).
Dated: October 10, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–22283 Filed 10–13–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
16:59 Oct 13, 2017
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1429]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Guidance for
Industry on Registration of Human
Drug Compounding Outsourcing
Facilities Under Section 503B of the
Federal Food, Drug, and Cosmetic Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by November
15, 2017.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0777. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUMMARY:
Guidance for Industry on Registration
of Human Drug Compounding
Outsourcing Facilities Under Section
503B of the Federal Food, Drug, and
Cosmetic Act OMB Control Number
0910–0777—Extension
This information collection supports
the above captioned Agency guidance.
A facility that compounds drugs may
elect to register with FDA as an
outsourcing facility under section 503B
of the Federal Food, Drug, and Cosmetic
Act (the FD&C Act) (21 U.S.C. 353b), as
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
added by the Drug Quality and Security
Act (DQSA). Drug products
compounded in a registered outsourcing
facility can qualify for exemptions from
the FDA approval requirements in
section 505 of the FD&C Act (21 U.S.C.
355), the requirement to label products
with adequate directions for use under
section 502(f)(1) of the FD&C Act (21
U.S.C. 352(f)(1)), and drug supply chain
security requirements in section 582 of
the FD&C Act (21 U.S.C. 360eee) if the
requirements in section 503B of the
FD&C Act are met.
After the initial registration, under
section 503B(b) of the FD&C Act, a
facility that elects to register with FDA
as an outsourcing facility must also do
so annually between October 1 and
December 31. Upon registration, the
outsourcing facility must provide its
name, place of business, a unique
facility identifier, and a point of contact
email address and phone number. The
outsourcing facility must also indicate
whether it intends to compound, within
the next calendar year, a drug that
appears on FDA’s drug shortage list in
effect under section 506E of the FD&C
Act (21 U.S.C. 356e), and whether it
compounds from bulk drug substances,
and, if so, whether it compounds sterile
or non-sterile drugs from bulk drug
substances.
Outsourcing facilities that elect to
register should submit the following
registration information to FDA for each
facility:
• Name of the facility;
• Place of business;
• Unique facility identifier;
• Point of contact email address and
phone number;
• Whether the facility intends to
compound drugs that appear on FDA’s
drug shortage list in effect under section
506E of the FD&C Act; and
• An indication of whether the
facility compounds from bulk drug
substances, and if so, whether it
compounds sterile or nonsterile drugs
from bulk drug substances.
Registration information should be
submitted to FDA electronically using
the Structured Product Labeling (SPL)
format and in accordance with section
IV of the FDA guidance entitled
‘‘Providing Regulatory Submissions in
Electronic Format—Drug Establishment
Registration and Drug Listing.’’ Under
the final guidance, outsourcing facilities
may request a waiver from the SPL
electronic submission process by
submitting a written request to FDA
explaining why the use of electronic
means is not reasonable.
In the Federal Register of June 20,
2017 (82 FR 28076), FDA published a
60-day notice requesting public
E:\FR\FM\16OCN1.SGM
16OCN1
48093
Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices
comment on the proposed collection of
information. No comments were
received.
We therefore estimate the burden
associated with the information
collection as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1
Electronic Submission of Registration Information Using
SPL Format ......................................................................
Waiver Request From Electronic Submission of Registration Information .................................................................
Dated: October 10, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
1
62
4.5
279
1
1
1
1
1
........................
........................
........................
........................
280
September 21, 2017 (82 FR 44185). The
document announced the withdrawal of
approval of 27 abbreviated new drug
applications (ANDAs) from multiple
applicants. The document was
published with the incorrect docket
number. This document corrects that
error.
Lisa
Granger, Office of Policy, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 3330, Silver Spring,
MD 20993–0002, 301–796–9115,
lisa.granger@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of Thursday,
September 21, 2017, in FR Doc. 2017–
20107, on page 44185 the following
correction is made:
On page 44185, in the second column,
under the docket number FDA–2017–N–
5526 is corrected to read ‘‘FDA–2017–
N–5226’’.
FOR FURTHER INFORMATION CONTACT:
Dated: October 11, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–22284 Filed 10–13–17; 8:45 am]
BILLING CODE 4164–01–P
Electronic Submissions
BILLING CODE 4164–01–P
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2017–N–5226]
Department of Health and Human
Services, Supply Service Center et al.;
Withdrawal of Approval of 27
Abbreviated New Drug Applications;
Correction
Food and Drug Administration,
HHS.
ethrower on DSK3G9T082PROD with NOTICES
Notice; correction.
The Food and Drug
Administration is correcting a notice
entitled ‘‘Department of Health and
Human Services, Supply Service Center
et al.; Withdrawal of Approval of 27
Abbreviated New Drug Applications’’
that appeared in the Federal Register of
SUMMARY:
VerDate Sep<11>2014
16:59 Oct 13, 2017
Jkt 244001
announcing the availability of a draft
guidance for industry entitled ‘‘PostComplete Response Letter Meetings
Between FDA and ANDA Applicants
Under GDUFA.’’ This guidance is
intended to clarify the criteria for
granting post-complete response letter
(CRL) meeting requests and the scope of
discussions for granted meeting
requests. This guidance provides
procedures that will promote wellmanaged post-CRL meetings and help
ensure that such meetings are scheduled
and conducted in accordance with the
time frames set forth in the GDUFA
Reauthorization Performance Goals and
Program Enhancements Fiscal Years
2018–2022 (GDUFA II Goals or
Commitment Letter).
DATES: Submit either electronic or
written comments on the draft guidance
by December 15, 2017 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
[FR Doc. 2017–22299 Filed 10–13–17; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
Total hours
are no capital costs or operating and maintenance costs associated with this collection of information.
We estimate that approximately 62
outsourcing facilities (‘‘number of
respondents’’ and ‘‘total annual
responses’’ in table 1, row 1) will
annually submit to FDA registration
information using the SPL format as
specified in the guidance, and that
preparing and submitting this
information will take approximately 4.5
hours per registrant (‘‘average burden
per response’’ in table 1, row 1). We
expect to receive no more than one
waiver request from the electronic
submission process annually (‘‘number
of respondents’’ and ‘‘total annual
responses’’ in table 1, row 2), and that
each request should take approximately
1 hour to prepare and submit to us
(‘‘average burden per response’’ in table
1, row 2).
AGENCY:
Average
burden per
response
Total annual
responses
62
Total ..............................................................................
1 There
Number of
responses per
respondent
Number of
respondents
Compounding outsourcing facility
Food and Drug Administration
[Docket No. FDA–2017–D–5928]
Post-Complete Response Letter
Meetings Between the Food and Drug
Administration and Abbreviated New
Drug Application Applicants Under the
Generic Drug User Fee Act; Draft
Guidance for Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
SUMMARY:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
E:\FR\FM\16OCN1.SGM
16OCN1
Agencies
[Federal Register Volume 82, Number 198 (Monday, October 16, 2017)]
[Notices]
[Pages 48092-48093]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22284]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1429]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Guidance for Industry
on Registration of Human Drug Compounding Outsourcing Facilities Under
Section 503B of the Federal Food, Drug, and Cosmetic Act
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
November 15, 2017.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0777.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-5733,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Guidance for Industry on Registration of Human Drug Compounding
Outsourcing Facilities Under Section 503B of the Federal Food, Drug,
and Cosmetic Act OMB Control Number 0910-0777--Extension
This information collection supports the above captioned Agency
guidance. A facility that compounds drugs may elect to register with
FDA as an outsourcing facility under section 503B of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 353b), as added by the
Drug Quality and Security Act (DQSA). Drug products compounded in a
registered outsourcing facility can qualify for exemptions from the FDA
approval requirements in section 505 of the FD&C Act (21 U.S.C. 355),
the requirement to label products with adequate directions for use
under section 502(f)(1) of the FD&C Act (21 U.S.C. 352(f)(1)), and drug
supply chain security requirements in section 582 of the FD&C Act (21
U.S.C. 360eee) if the requirements in section 503B of the FD&C Act are
met.
After the initial registration, under section 503B(b) of the FD&C
Act, a facility that elects to register with FDA as an outsourcing
facility must also do so annually between October 1 and December 31.
Upon registration, the outsourcing facility must provide its name,
place of business, a unique facility identifier, and a point of contact
email address and phone number. The outsourcing facility must also
indicate whether it intends to compound, within the next calendar year,
a drug that appears on FDA's drug shortage list in effect under section
506E of the FD&C Act (21 U.S.C. 356e), and whether it compounds from
bulk drug substances, and, if so, whether it compounds sterile or non-
sterile drugs from bulk drug substances.
Outsourcing facilities that elect to register should submit the
following registration information to FDA for each facility:
Name of the facility;
Place of business;
Unique facility identifier;
Point of contact email address and phone number;
Whether the facility intends to compound drugs that appear
on FDA's drug shortage list in effect under section 506E of the FD&C
Act; and
An indication of whether the facility compounds from bulk
drug substances, and if so, whether it compounds sterile or nonsterile
drugs from bulk drug substances.
Registration information should be submitted to FDA electronically
using the Structured Product Labeling (SPL) format and in accordance
with section IV of the FDA guidance entitled ``Providing Regulatory
Submissions in Electronic Format--Drug Establishment Registration and
Drug Listing.'' Under the final guidance, outsourcing facilities may
request a waiver from the SPL electronic submission process by
submitting a written request to FDA explaining why the use of
electronic means is not reasonable.
In the Federal Register of June 20, 2017 (82 FR 28076), FDA
published a 60-day notice requesting public
[[Page 48093]]
comment on the proposed collection of information. No comments were
received.
We therefore estimate the burden associated with the information
collection as follows:
Table 1--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
Number of
Compounding outsourcing facility Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Electronic Submission of 62 1 62 4.5 279
Registration Information Using
SPL Format.....................
Waiver Request From Electronic 1 1 1 1 1
Submission of Registration
Information....................
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 280
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
We estimate that approximately 62 outsourcing facilities (``number
of respondents'' and ``total annual responses'' in table 1, row 1) will
annually submit to FDA registration information using the SPL format as
specified in the guidance, and that preparing and submitting this
information will take approximately 4.5 hours per registrant (``average
burden per response'' in table 1, row 1). We expect to receive no more
than one waiver request from the electronic submission process annually
(``number of respondents'' and ``total annual responses'' in table 1,
row 2), and that each request should take approximately 1 hour to
prepare and submit to us (``average burden per response'' in table 1,
row 2).
Dated: October 10, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-22284 Filed 10-13-17; 8:45 am]
BILLING CODE 4164-01-P